Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6161799 | 1.00 | TRPV1 (0.44) | TRPV1PLA2G2AHCRTR1HCRTR2MAPT | |
| SCHEMBL6163055 | 1.00 | TRPV1 (0.44) | TRPV1PLA2G2AHCRTR1HCRTR2MAPT | |
| SCHEMBL6163699 | 0.89 | POLB (0.55) | TRPV1HCRTR1HCRTR2MAPTPOLB | |
| SCHEMBL6163817 | 0.89 | POLB (0.55) | TRPV1HCRTR1HCRTR2MAPTPOLB | |
| SCHEMBL6165715 | 0.89 | POLB (0.55) | TRPV1HCRTR1HCRTR2MAPTPOLB | |
| SCHEMBL6161806 | 0.85 | TRPV1 (0.46) | TRPV1HCRTR1HCRTR2MAPTPOLB | |
| SCHEMBL6163596 | 0.85 | TRPV1 (0.46) | TRPV1HCRTR1HCRTR2MAPTPOLB | |
| SCHEMBL6162253 | 0.85 | TRPV1 (0.46) | TRPV1HCRTR1HCRTR2MAPTPOLB | |
| SCHEMBL6163166 | 0.81 | RAB9A (0.53) | HCRTR1HCRTR2POLBKDM4EHSP90AA1 | |
| SCHEMBL6162969 | 0.81 | RAB9A (0.53) | HCRTR1HCRTR2POLBKDM4EHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337523-B1 | 2,4-SUBSTITUTED PYRIDINE DERIVATIVES | NEUROGEN CORP (US) | 2005-10-19 | — | — | EP | claimed |
| US-20040048867-A1 | 2,4-Substituted pyridine derivatives | NEUROGEN CORPORATION | 2004-03-11 | — | — | US | claimed |
| EP-1337523-A2 | 2,4-SUBSTITUTED PYRIDINE DERIVATIVES | NEUROGEN CORPORATION (US) | 2003-08-27 | — | — | EP | claimed |
| US-6559163-B2 | Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression | NEUROGEN CORPORATION | 2003-05-06 | — | — | US | claimed |
| US-20020161008-A1 | 2,4-Substituted pyridine derivatives | NEUROGEN CORPORATION | 2002-10-31 | — | — | US | claimed |
| WO-2002014269-A2 | 2,4-SUBSTITUTED PYRIDINE DERIVATIVES | NEUROGEN CORPORATION (US) | 2002-02-21 | — | — | WO | claimed |
| EP-1379511-B1 | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | HOFFMANN LA ROCHE (CH) | 2005-07-20 | — | — | EP | disclosed |
| US-6559163-B2 | Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression | NEUROGEN CORPORATION | 2003-05-06 | — | — | US | disclosed |
| US-6544985-B2 | For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits | HOFFMAN-LA ROCHE INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | CYP1B1, GRIN2B, BDKRB1 | TRPV1 776/4885PLA2G2A 3011/4885HCRTR1 235/4885 |
| US-20020161008-A1 | 2,4-Substituted pyridine derivatives | GABARAP, GABRB1, GABARAPL1 | TRPV1 1234/4885PLA2G2A 1847/4885HCRTR1 81/4885 |
| US-20040048867-A1 | 2,4-Substituted pyridine derivatives | GABARAP, GABRB1, GABARAPL1 | TRPV1 1234/4885PLA2G2A 1847/4885HCRTR1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.